Mark Zitter, MBA, Discusses Implications of Co-Pay Offset Programs for Managed Care

In this video, Mark Zitter, MBA, talks about the implications of Co-Pay Offset Programs for managed care. "Co-pay programs affect managed care very differently depending on the nature of the program," says Zitter. "These programs are tremendously varied."

Related Videos

Related Content

Advertisement

July 3rd 2025

A Closer Look at Nipocalimab’s Impact on Myasthenia Gravis Care: Constantine Farmakidis, MD

Maggie L. Shaw Constantine Farmakidis, MD

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

June 24th 2025

Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

Maggie L. Shaw Richard J. Nowak, MD, MS

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 19th 2025

Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD

Hayden E. Klein Hamlet Gasoyan, PhD

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.

June 19th 2025

Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

Julia Bonavitacola Onyema Ogbuagu, MBBCh, FACP, FIDSA

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

Related Content

Advertisement

July 3rd 2025

A Closer Look at Nipocalimab’s Impact on Myasthenia Gravis Care: Constantine Farmakidis, MD

Maggie L. Shaw Constantine Farmakidis, MD

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

June 24th 2025

Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

Maggie L. Shaw Richard J. Nowak, MD, MS

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 19th 2025

Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD

Hayden E. Klein Hamlet Gasoyan, PhD

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.

June 19th 2025

Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

Julia Bonavitacola Onyema Ogbuagu, MBBCh, FACP, FIDSA

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.